

EXAMINER'S AMENDMENT

1. An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Applicant representative, Mr. Thomas Friebe on 1/14/2008.

The application has been amended as follows:

Replace all previously amended claims with the following listing of claims:

Listing of Claims:

1-16. (canceled)

17. (currently amended) A method of treating endometriosis in a subject having endometriosis comprising administering to the subject an amount of an indole selected from the group consisting of 3,3'-Diindolylmethane (DIM), 2-(Indol-3-ylmethyl)- 3,3'-Diindolylmethane (LTr-1) and Indole-3-carbinol (I3C) effective to reduce one or more symptoms associated with endometriosis, wherein the indole is formulated as a tablet, pill, capsule, suppository, cream, parenteral suspension or liposomal spray, or is suspended as microparticles in a starch carrier matrix.

18. (currently amended) The method according to claim 17, wherein the symptom is selected from the group consisting of pain, dysplasia, and the level Ca-125 antigen detectable in serum.

19. (currently amended) The method according to claim 17, wherein the indole is I3C.

20. (currently amended) The method of claim 17, wherein the indole is DIM.

21. (original) The method of claim 20, wherein the DIM is suspended as microparticles in a starch carrier matrix.

22. (currently amended) The method of claim 17, wherein the indole is LTr-1.

23-33. (canceled)

34. (previously presented) The method of claim 17, further comprising administering grapefruit, grapefruit concentrate, grapefruit juice, or grapefruit juice concentrate.

35-42. (canceled)

43. (new) The method of claim 19, 20 or 22, wherein the indole is suspended as microparticles in a starch carrier matrix.

44. (new) The method of claim 17, wherein the indole is formulated as a tablet.

45. (new) The method of claim 17, wherein the indole is formulated as a pill.

46. (new) The method of claim 17, wherein the indole is formulated as a capsule.

47. (new) The method of claim 17, wherein the indole is formulated as a suppository.

48. (new) The method of claim 17, wherein the indole is formulated as a cream.

49. (new) The method of claim 17, wherein the indole is formulated as a parenteral suspension.

50. (new) The method of claim 17, wherein the indole is formulated as a liposomal spray.
51. (new) The method of claim 17, wherein the indole is suspended as microparticles in a starch carrier matrix.
51. (new) The method of claim 44-46, wherein the indole is administered orally.
52. (new) The method of claim 47, 48 or 50, wherein the indole is administered by direct application to the vaginal or cervical mucosa of the subject.
53. (new) The method of claim 47, 48 or 50, wherein the indole is administered transdermally.

Correspondence

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Nabila G. Ebrahim whose telephone number is 571-272-8151. The examiner can normally be reached on 8:00AM-5:00PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Michael Hartley can be reached on 571-272-0616. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Application/Control Number:
10/765,792
Art Unit: 1618

Page 5

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Michael G. Hartley/
Supervisory Patent Examiner, Art Unit 1618

Nabila Ebrahim
1/20/08